BC Innovations | Aug 6, 2015
Product R&D

Impede a fever

A team at the Massachusetts Institute of Technology has developed an antibody that could treat dengue infections caused by all four serotypes of the virus, and might be able to prevent the disease as well....
BC Week In Review | Nov 25, 2013
Clinical News

Anti-dengue nanoviricides regulatory update

NanoViricides said the European Commission granted Orphan Drug designation for DengueCide to treat dengue and dengue hemorrhagic fever. The vaccine is in preclinical testing and has Orphan Drug designation in the U.S. DengueCide consists of...
BC Week In Review | Aug 19, 2013
Clinical News

DengiCide regulatory update

NanoViricides said FDA granted Orphan Drug designation for DengueCide to treat dengue and dengue hemorrhagic fever. The company also said it is seeking Orphan Drug designation in the EU. The vaccine, which is in preclinical...
BC Week In Review | Jul 19, 2010
Clinical News

NanoViricides preclinical data

In animals infected with dengue virus, 50% of those treated with a single anti-dengue nanoviricide survived. Furthermore, animals treated with several anti-dengue nanoviricides survived longer than vehicle-treated control animals. The DengueCide project consists of nanoviricides...
BC Week In Review | Jul 19, 2010
Clinical News

NanoViricides preclinical data

Cell culture studies showed that several anti-dengue nanoviricides dose-dependently inhibited serotype dengue virus 2 infectivity. NanoViricides said it believes a broad-spectrum nanoviricide that is highly effective against all 4 dengue virus serotypes is now feasible....
Items per page:
1 - 5 of 5